Developing therapeutic monoclonal antibodies and ADC's is a key focus of the pharmaceutical industry's R&D. The European Antibody Congress 2012 bought together senior level executives and opinion leaders from around the globe to further their knowledge and engage in discussion on a variety of topics relating to mAbs, ADC's and bispecifics. Attendees at this highly successful event were fortunate enough to hear this exciting presentation delivered by Alain Beck, Head of Physico-Chemistry Department, Centre d'Immunologie Pierre Fabre; Associate Editor, mAbs, âAntibody structure-guided optimization: OptimAbs'.
This presentation focuses on:
Â· Antibody lead optimization based on emergent mass spectrometry methods
Â· Improving antibody developability by identification of Critical Quality Attributes
Â· Gaining insights in structure-function relationships by analyzing antibody/ antigen complexes
Are you interested in learning more and engaging in discussion on mAbs, ADC's, bispecifics and antibody biosimilars? Do you want to hear the most recent updates on mAbs/ADC's at the clinical stage? Do you want to network with senior executives and opinion leaders from truly international antibody pioneers? Take a look at the European Antibody Congress 2013.
Alain Beck will once again be returning to the European Antibody Congress as a speaker in 2013.